Du Pont Merck Pharmaceuticalreceived approval last month from the Food and Drug Administrationfor Neurolite, a technetium-tagged brain SPECT imaging agent.Neurolite becomes the second brain SPECT agent on the market,joining Amersham's Ceretec, also a
Du Pont Merck Pharmaceuticalreceived approval last month from the Food and Drug Administrationfor Neurolite, a technetium-tagged brain SPECT imaging agent.Neurolite becomes the second brain SPECT agent on the market,joining Amersham's Ceretec, also a technetium-labeled agent. DuPont Merck, of North Billerica, MA, plans to begin shipping Neurolitein January. The product is indicated for brain perfusion studiesin stroke patients (SCAN 9/14/94).